News stories about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended somewhat positive on Saturday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.9105683969111 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Leerink Swann Trims Regeneron Pharmaceuticals (REGN) Target Price to $502.00 (americanbankingnews.com)
- Regeneron Pharmaceuticals (REGN) Price Target Raised to $415.00 (americanbankingnews.com)
- Regeneron Pharmaceuticals (REGN) PT Set at $430.00 by SunTrust Banks (americanbankingnews.com)
- Updating The Bullish Case For Regeneron As The Stock Drops – Seeking Alpha (seekingalpha.com)
- Analyst: Regeneron Is Undervalued By The Street (finance.yahoo.com)
REGN has been the topic of several recent research reports. Citigroup reiterated a “buy” rating and issued a $480.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 9th. Guggenheim reiterated a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Canaccord Genuity reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Piper Jaffray Companies reiterated a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, November 13th. Finally, BTIG Research reissued a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $463.19.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the firm posted $3.04 EPS. The company’s revenue was up 28.9% on a year-over-year basis. equities research analysts anticipate that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/10/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-regeneron-pharmaceuticals-regn-stock-price.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.